Answers are grounded in this paper and cite their sources.
(MRSA) bacteremia continues to cause significant morbidity and mortality despite advances in medical therapy. Vancomycin therapy remains the standard of care for most cases of MRSA bacteremia but has pharmacokinetic and pharmacodynamic limitations, dosing complications, and known toxicity. Welcomed clinical trials have recently addressed some of the controversies that plague this field, including optimization of vancomycin dosing and use of combination therapy. In this review, we discuss these trials and their implications for clinical care and future research.
No takes yet. Share an insight, caveat, or question.
Suárez et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: